Advertisement
U.S. markets open in 5 hours 10 minutes

IO Biotech, Inc. (IOBT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
0.8200-0.0700 (-7.87%)
At close: 04:00PM EST
0.8077 -0.01 (-1.50%)
After hours: 04:41PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.8900
Open0.8949
Bid0.7884 x 100
Ask0.8453 x 300
Day's Range0.7901 - 0.8949
52 Week Range0.7330 - 2.0980
Volume377,604
Avg. Volume474,032
Market Cap54.022M
Beta (5Y Monthly)0.42
PE Ratio (TTM)N/A
EPS (TTM)-1.2600
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
  • GlobeNewswire

    IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

    Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced melanoma on track with primary endpoint of progression free survival (PFS) projected to be reached in first half of 2025Primary endpoint met in Phase 2 basket trial (IOB-022/KN-D38) cohort evaluating IO102-IO103 in combination with pembrolizumab in the first-line treatment of advanced squamous cell

  • GlobeNewswire

    IO Biotech Announces Participation in Upcoming Investor Conferences

    NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that members of its senior management team will participate in the following upcoming investor conferences: Event: Jefferies London Healthcare ConferenceLocation: LondonOne-on-one meetings: Wednesday, November 20, 2024Participants: Mai-Britt Zocca, PhD, Preside